Published in Oncogene on April 01, 2013
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
mTOR pathway in colorectal cancer: an update. Oncotarget (2014) 1.15
Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia (2014) 0.97
Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PLoS One (2014) 0.95
mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene (2015) 0.95
AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget (2015) 0.93
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood (2016) 0.87
4E-BP1, a multifactor regulated multifunctional protein. Cell Cycle (2016) 0.86
Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition. Sci Rep (2016) 0.84
eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget (2015) 0.82
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Res (2016) 0.81
PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer. Oncogene (2015) 0.81
Tivozanib in the treatment of renal cell carcinoma. Biologics (2013) 0.80
Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia. J Transl Med (2014) 0.79
New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell Microenviron (2015) 0.79
BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget (2016) 0.78
Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1. Oncogenesis (2015) 0.77
Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384. Clin Cancer Res (2015) 0.77
4E-BP1 as an oncotarget. Aging (Albany NY) (2015) 0.76
Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. Oncotarget (2016) 0.75
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clin (2015) 0.75
High Inorganic Phosphate Intake Promotes Tumorigenesis at Early Stages in a Mouse Model of Lung Cancer. PLoS One (2015) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
mTOR signaling in growth control and disease. Cell (2012) 29.21
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res (2003) 3.30
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol (2008) 2.58
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett (2008) 2.28
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg (2010) 1.98
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene (2011) 1.92
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer (2010) 1.91
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene (2010) 1.85
Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA (2008) 1.69
eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res (2012) 1.62
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today (2011) 1.52
Searching for synthetic lethality in cancer. Curr Opin Genet Dev (2011) 1.34
Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. Methods Enzymol (2001) 1.23
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer (2012) 0.98
p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ Res (2012) 0.98
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs (2012) 0.86
Predictive molecular classifiers in colorectal cancer. Semin Oncol (2011) 0.86